Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €0.03 EUR
Change Today -0.003 / -8.33%
Volume 11.1K
AGX On Other Exchanges
As of 7:15 AM 03/31/15 All times are local (Market data is delayed by at least 15 minutes).

agennix ag (AGX) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/31/14 - €0.08
52 Week Low
01/14/15 - €0.0090
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for AGENNIX AG (AGX)

Related News

No related news articles were found.

agennix ag (AGX) Related Businessweek News

No Related Businessweek News Found

agennix ag (AGX) Details

Agennix AG operates as a biopharmaceutical company in Princeton, New Jersey. It focuses on developing novel therapies that have the potential to lengthen and enhance the lives of critically ill patients in areas of unmet medical need. The company’s lead product candidate under development is Talactoferrin, an oral dendritic cell that establishes and functions body’s immune system, which has completed Phase III trial enrollment for the treatment of non-small cell lung cancer; and Phase II clinical trial for the treatment of severe sepsis. Its developmental stage products include topical talactoferrin, which has completed Phase IIa clinical trial for the treatment of diabetic foot ulcers; satraplatin, an oral platinum gel that has completed Phase I trial for oncology; and RGB-286638, a multi-targeted kinase inhibitor that has completed Phase I trial for the treatment of solid tumors. The company is based in Heidelberg, Germany.

52 Employees
Last Reported Date: 11/30/12

agennix ag (AGX) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

agennix ag (AGX) Key Developments

Agennix AG Approves Amendments to Articles of Association

Agennix AG announced that at its extraordinary general meeting held on May 22, 2013, the shareholders approved amendments to the articles of association to reduce the size of the Supervisory Board of company from six to three members.

Agennix AG, Special/Extraordinary Shareholders Meeting, May 22, 2013

Agennix AG, Special/Extraordinary Shareholders Meeting, May 22, 2013. Agenda: To consider proposals for the liquidation of the company and a 20:1 reverse stock split.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AGX:GR €0.03 EUR -0.003

AGX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AGX.
View Industry Companies

Industry Analysis


Industry Average

Valuation AGX Industry Range
No financial data is available for AGX.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AGENNIX AG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at